|

ARD103 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • ARCE Therapeutics, Inc.1

Indications

  • MDS (Myelodysplastic Syndrome)1
  • Acute Myeloid Leukemia, in Relapse1
  • Acute Myeloid Leukemia Refractory1
  • Cancer1

Charlotte, North Carolina1 trial

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Novant Health Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.